Skip to content

Psychedelic-assisted therapy: all studies

Page 189 of 294: studies 1,881 to 1,890 of 2,936, newest first. Back to the psychedelic-assisted therapy overview

Research

KETAMINE: Neural- and network-level changes.

Neuroscience November 1, 2024 Vishal Bharmauria, Hamidreza Ramezanpour, Afef Ouelhazi et al.

Ketamine is a widely used clinical drug that has several functional and clinical applications, including its use as an anaesthetic, analgesic, anti-depressive, anti-suicidal agent, among others. Among its diverse behavioral effects, it influences short-term memory and induces psychedelic effects. At the neural level across different brain areas, it modulates neural firing rates, neural tuning,...

Psilocybin for major depressive disorder: An updated systematic review and meta-analysis of randomized clinical trials

Journal of Psychopharmacology October 31, 2024 Sepehr Aghajanian, Arman Shafiee, Samira Parvizi Omran et al. 12 citations

Background: Due to the unsatisfactory therapeutic effects of current antidepressants, research has been launched into alternative treatment approaches, such as the administration of psychedelics. Psilocybin, a classic hallucinogen, has been shown to exert considerable positive influence on depression symptoms through its serotonergic and glutamatergic effects. This systematic review and...

Acute Psychedelic Reactions, Post-Acute Changes in Dysfunctional Attitudes, and Psychedelic-Associated Changes in Wellbeing.

Journal of Psychoactive Drugs October 30, 2024 Mitch Earleywine, Genevieve S. Falabella, Alyssa B. Oliva et al. 3 citations

Dysfunctional attitudes - a cornerstone to cognitive psychotherapy - vary with both psychological and pharmacological interventions. Post-acute changes in these cognitions appear to covary with the acute reactions to psychedelics that often precede improved outcomes. An examination of post-acute changes in dysfunctional attitudes could support targeting them in psychedelic-assisted therapy....

DOI: 10.1080/02791072.2024.2421892 (opens in new tab) Psychedelics Hallucinogens Entheogens Psychotropic substances +17

“The mushroom was more alive and vibrant”: Patient reports of synthetic versus organic forms of psilocybin

Journal of Psychedelic Studies October 29, 2024 Pamela Kryskow, Paul Stamets, Joseph T. la Torre et al. 4 citations

Abstract Interest in psychedelic research in the West is surging, however, clinical trials have almost exclusively studied synthetic compounds such as MDMA, ketamine, DMT, LSD, ibogaine, and psilocybin. To date, few clinical trials have utilized whole mushroom/plant material like Psilocybe mushrooms, Iboga, or Ayahuasca. Individuals participating in the Roots To Thrive Psilocybin-Assisted...

Anxiety and Affective Symptoms Related to the Use of Classic Psychedelics: A Systematic Review.

Current Topics in Behavioral Neurosciences October 23, 2024 Grace Viljoen, Felix Betzler 5 citations

There is a large and rapidly growing body of literature investigating the therapeutic effects of classic psychedelics in affective and anxiety disorders, but very few studies have examined the inverse of this, that is, the potential for psychedelics to inflict anxiety and affective symptoms. A systematic literature search was performed and 39 papers were included in the final review to...

Meditation, Psychedelics, and Their Pitfalls

October 22, 2024 Jan Benda

In this chapter, the roles of meditation and psychedelics within personal and transpersonal development are explored, challenging the notion that these experiences alone lead to personal growth. It highlights the importance of therapeutic contexts in integrating these experiences to address maladaptive schemas and foster therapeutic change. The chapter emphasizes that a journey toward an...

Psicoterapias assistidas por MDMA no tratamento do estresse pós-traumático em adultos: uma revisão integrativa

Revista Sociedade Científica October 22, 2024 Manuela Bahia Almeida da Franca, Sandra Regina Mota Ortiz

O Transtorno do Estresse Pós-Traumático (TEPT) é caracterizado por um conjunto de sinais e sintomas associados a um profundo sofrimento psicológico após a vivência ou testemunha de um episódio traumático. Apesar de muito prevalente na população, a abordagem atual do transtorno possui importantes limitações, o que afeta de maneira significativa a qualidade de vida dos afetados. Diante desse...

The forgotten psychedelic: Spatiotemporal mapping of brain organisation following the administration of 2C-B and psilocybin

bioRxiv (Cold Spring Harbor Laboratory) October 22, 2024 Pablo Mallaroni, S. Parker Singleton, Natasha L. Mason et al. 2 citations preprint

As psychedelic-assisted psychotherapy gains momentum, clinical investigation of next-generation psychedelics may lead to novel compounds tailored for specific populations. 2,5-dimethoxy-4-bromophenethylamine (2C-B) is a psychedelic phenethylamine reported to produce less dysphoria and subjective impairment than the psychedelic tryptamine psilocybin. Despite its popularity among recreational...

DOI: 10.1101/2024.10.22.619393 (opens in new tab) Full text (opens in new tab) Psilocybin Hallucinogen Administration probate law Cognitive psychology

Psychedelics and the treatment of eating disorders: considerations for future research and practice.

Journal of Eating Disorders October 22, 2024 Emilie Lacroix, Karsten Fatur, Phillipa Hay et al. 12 citations

Recent trials have shown promising results for the use of psychedelic-assisted therapies in treating severe refractory psychiatric illnesses, and there has been growing interest in examining the effectiveness of these therapies in treating eating disorders. To move forward in a safe, ethically sound, and scientifically rigorous manner, the field must address critical considerations. In this...

DOI: 10.1186/s40337-024-01125-6 (opens in new tab) Full text (opens in new tab) Psychedelics Mental health treatment Eating disorders Therapeutic research +1

Stephanie Knatz Peck: Novel and innovative treatment for eating disorders

Psychedelics October 21, 2024 Stéphanie Knatz Peck

Dr. Stephanie Knatz Peck, Ph.D., is a practicing clinical psychologist and Associate Clinical Professor of Psychiatry at the University of California, San Diego (UCSD). Her career uniquely bridges clinical practice with innovative research, focusing on developing and evaluating novel psychiatric interventions, particularly for eating disorders. Dr. Knatz Peck's research journey began at the...

DOI: 10.61373/pp024k.0031 (opens in new tab) Peck imperial Eating disorders Psychoanalysis Psychotherapist